N. Pécuchet

发表

Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples.

P. Laurent-Puig, B. Rance, H. Blons, 2018, The Journal of molecular diagnostics : JMD.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities

P. Laurent-Puig, H. Blons, M. Antoine, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas

A. Vincent-Salomon, M. Bollet, C. Lucchesi, 2013, International journal of cancer.

Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer

S. Imbeaud, P. Laurent-Puig, H. Blons, 2017, Cancers.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

P. Laurent-Puig, I. Cremer, K. Leroy, 2018, Clinical Cancer Research.

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.

P. Laurent-Puig, I. Cremer, E. Becht, 2016, American journal of respiratory and critical care medicine.

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas

I. Bièche, P. Laurent-Puig, E. Pasmant, 2019, Cancer medicine.

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer

Pierre Laurent-Puig, Françoise Le Pimpec-Barthes, Diane Damotte, 2015, Oncotarget.

[Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].

P. Laurent-Puig, H. Blons, A. Legras, 2016, Annales de pathologie.

[Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013].

F. Bigot, E. Fabre, N. Pécuchet, 2014, Revue de pneumologie clinique.

Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA.

Y. Rozenholc, P. Laurent-Puig, H. Blons, 2016, Clinical chemistry.

Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker

Valérie Taly, Pierre Laurent-Puig, P. Laurent-Puig, 2016, Clinical Cancer Research.

Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.

Y. Allory, B. Escudier, S. Oudard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

P. Laurent-Puig, K. Leroy, H. Blons, 2018, Revue de pneumologie clinique.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Roman K. Thomas, F. Cappuzzo, E. Smit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord–Stromal Tumors: A Systematic Review and Meta-analysis

S. Oudard, E. Pujade-Lauraine, P. Combe, 2015, International Journal of Gynecologic Cancer.

New Insights into the Management of Renal Cell Cancer

S. Oudard, L. Fournier, N. Pécuchet, 2012, Oncology.

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

C. Lebbé, F. Goldwasser, R. Coriat, 2012, British Journal of Cancer.

[Implications of ALK (anaplastic lymphoma kinase) in oncohematology].

N. Mounier, T. Cluzeau, S. Vignot, 2010, Bulletin du cancer.

Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study

Y. Rozenholc, P. Laurent-Puig, H. Blons, 2016, PLoS medicine.

Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).

Y. Allory, S. Oudard, G. Gravis, 2023, European journal of cancer.

724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)

Y. Allory, S. Oudard, G. Gravis, 2020 .

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank

J. Pastre, P. Laurent-Puig, M. Neri, 2017, BMC Public Health.

Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations

Karla Perez-Toralla, Valérie Taly, Pierre Laurent-Puig, 2016, PloS one.

IDNetwork: A deep illness‐death network based on multi‐state event history process for disease prognostication

S. Katsahian, A. Guilloux, N. Pécuchet, 2022, Statistics in medicine.

IDNetwork: A deep Illness-Death Network based on multi-states event history process for versatile disease prognostication

S. Katsahian, A. Guilloux, N. Pécuchet, 2021, SPACA.

[Histone deacetylase inhibitors: highlight on epigenetic regulation].

N. Mounier, T. Cluzeau, C. Thibault, 2010, Bulletin du cancer.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

H. Blons, X. Mignard, C. Hamard, 2018, Revue de pneumologie clinique.

New Insights into the Management of Renal Cell Cancer

S. Oudard, L. Fournier, N. Pécuchet, 2012, Oncology.

[Obesity and lung cancer: incidence and repercussions on epidemiology, pathology and treatments].

F. L. Pimpec-Barthes, M. Riquet, D. Wermert, 2015, Revue de pneumologie clinique.

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer

P. Laurent-Puig, M. Riquet, H. Blons, 2015, Oncotarget.

[What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers].

P. Laurent-Puig, H. Blons, V. Taly, 2016, Bulletin du cancer.